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Abstract
Background: Multiple studies have reported evidence of an inverse association between parity and bladder cancer
risk. However, a comprehensive and quantitative assessment of this association has never been conducted. We
conducted this study to clarify this issue.
Methods: Systematic search of PubMed and Embase was performed to identify all the studies. Studies were
selected based on strict screening with inclusion and exclusion criteria. Summary relative risks (RR) with 95%
confidence intervals (CI) were calculated by using a fixed-effect model, and the generalized least squares trend
estimation was employed to compute study-specific RR and 95% CI per live birth increase. Heterogeneity and
publication bias were also evaluated.
Results: Twelve studies (6,214 cases and 2,693,350 non-cases) were eligible in this meta-analysis. The pooled RR of
bladder cancer for parous versus nulliparous women was 0.76 (95% CI: 0.70–0.82). Results were similar in the studies
that adjusted for BMI(RR = 0.66; 95% CI: 0.53–0.81), cigarette smoking (RR = 0.67; 95% CI: 0.57–0.79), and age
(RR = 0.77; 95% CI: 0.71–0.84). The dose-response meta-analysis showed a lower bladder cancer risk (RR = 0.95;
95% CI: 0.92–0.98) for each live birth increase in parous women. No evidence of publication bias or significant
heterogeneity was detected in the above-mentioned analyses.
Conclusions: The finding from current meta-analysis suggest that parity may be related to decreased risk of
bladder cancer.
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Background
Bladder cancer (BC) is one of the most common genito-
urinary malignancies in the United States, with an
estimated 76, 960 newly diagnosed cases and 16 390
deaths in 2016 [1]. Incidence rate of BC is notably
gender-specific with men having a 3~4 fold greater risk
than women for developing the disease [1]. Given the
evidence from current knowledge, the gender disparity
of incidence rate for BC cannot be completely explained
by known risk factors, such as cigarette smoking and
occupation [2].
Although the exact biological mechanisms for the
gender disparity in BC development and progression are
not well established, some studies have suggested that
sex hormones and their receptors may contribute to this
difference [3–5]. During pregnancy, changes in maternal
hormones, as well as physical structure changes in the
pelvic or lower abdominal region following childbirth,
may lead to etiological changes that decrease BC risk.
Till date, numerous observational studies [6–11] have
investigated the roles of reproductive factors, such as
age at menarche and menopause, parity, age at first
birth, and number of children, in the development of
BC, but results have been inconsistent, probably because
of limited sample size included each individual study.
Although published reviews and meta-analyses have fo-
cused on this topic [12, 13], up to now, a comprehensive
and quantitative assessment of the relationship between
parity number and BC risk has not been reported.
Therefore, we find it necessary to further assess the
relationship between parity and BC risk by conducting a
meta-analysis of current epidemiologic studies and
providing a quantitative dose-response analysis.
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Methods
This study protocol was approved by the institutional re-
view board at the West China School of Medicine before
initiation and don’t need ethical standard statement.
Literature search and eligibility criteria
We searched online databases MEDLINE and EMBASE
for the studies assessing the relationship of parity and
BC risk before Sep 2016, using the following terms with
every possible combination considered: parity, pregnancy,
reproductivity, fertility, bladder, genitourinary tract, can-
cer, carcinoma, tumor. We searched the references of all
eligible publications to identify additional relevant publi-
cations. Studies were included if they met the following
criteria: (1) the study had a prospective or case-control
design; (2) the study evaluated the relationship between
parity and BC risk; (3) data were provided or would allow
the calculation of relative risk (RR) or odds ratio (OR) and
a 95% confidence intervals (CI). Exclusion criteria were as
follows: (1) was not involved with the associations be-
tween parity and BC risk; (2) non-human studies, reviews,
and comments; (3) studies not reporting primary out-
comes; (4) studies based on overlapping patients. When
duplicate publications were identified or data in separate
publications originated from the same cohort, we used the
publication with the largest number of cases and the most
applicable data.
Data extraction and quality assessment
Data were independently extracted from the included
studies by two investigators (YJB and XMW), and
disagreement was settled by discussion with the third
investigator. The following data were extracted from
each study: first author’ name, publication year, country
of study, participant demographics, sample size, duration
of follow-up or study period, parity number categories,
corresponding OR/RR (with their 95% CIs) for each
category, and variables adjusted for in the analysis.
The methodological quality assessment was conducted
for each of the included studies using the Newcastle-
Ottawa Scale quality assessment [14] on three broad
perspectives: selection, comparability and exposure or
outcome. Two investigators read each included study
and scored them independently. Disagreements were
resolved by consensus.
Statistical analysis
Given that bladder cancer is a rare disease, the OR was
assumed to be the same as the RR and we therefore
report all effect sizes as RR for simplicity. We calculated
summary RRs and 95% CIs associated with parity and
BC risk, if the study considered nulliparous as a refer-
ence. Between-study heterogeneity was evaluated with Q
and I2 statistics [15]. For the Q-test, we used P < 0.10 as
evidence of heterogeneity. An I2 score exceeding 50% is
considered to indicate the presence of heterogeneity.
The random effect model was used to provide summary
estimations if there was heterogeneity, or else the fixed
effect model was used. Heterogeneity was explored by
stratified analysis. Publication bias was explored using
Begg’s and Egger’s test [16, 17] and funnel plots. P < 0.05
indicated the existence of publication bias.
We carried out a dose-response meta-analysis using
the method proposed by Greenland et al. [18] and Orsini
et al. [19] to estimate study-specific slopes (linear trends)
and 95% CIs from the log-RRs and CIs across the
categories of parity number. This analysis requires the
number of cases and controls for case-control studies or
the number of cases and person-years for cohort studies,
and the RR with 95% CI for at least three quantitative
categories of parity number are presented. The value
assigned to each category was the midpoint of the upper
and lower boundaries and was adjusted for half range of
the neighborhood categories when categories were open-
ended. Random-effects model was applied in our study.
This was done by modeling parity number using re-
stricted cubic splines with three knots at percentiles 5,
50, and 95% of the distribution. A P value for nonlinea-
rity was computed by testing the null hypothesis that the
coefficient of the second spline was equal to zero. Statis-
tical analyses were performed with Stata version 12.0
software (Stata Corp, College Station, TX).
Results
Study characteristics and quality assessment
The article selection process is shown in Fig. 1. Thirteen
articles [6–13, 20–24] met the selection criteria. Two
studies reported data on the same cohort [9, 22] and we
included the more recently one which reported the
Fig. 1 Flow diagram of the study selection process
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largest number of cases [22]. Thus, 12 publications were
included in this meta-analysis [6–8, 10–13, 20–24], and
their characteristics are presented in Table 1. These
studies included a total of 6,214 cases and 2,693,350
non-cases and were published from 1992 to 2013.
Among these studies, one study reported three separate
outcomes: the Los Angeles Bladder Cancer Study, the
Shanghai Bladder Cancer Study, and the California
Teachers Study [13]. Thus, the present study used
seven outcomes from case-control studies and seven
outcomes from cohort studies to produce a meta-
analysis. Of the included studies, 13 were conducted
in Europe, nine in America and one in China. All
studies included met quality criteria ranging from 5
to 7 stars.
Ever versus never parity
All included studies in present study investigated the
association between ever parity and BC risk. The sum-
mary multivariable-adjusted RR of BC for ever versus
nulliparous was 0.76 (95% CI, 0.70–0.82), without
heterogeneity (I2 = 0%, p = 0.795, Fig. 2), indicating an
inverse association between parity and BC risk. For
women who have never smoked, the summary RR of BC
for ever versus nulliparous was 0.47 (95% CI, 0.35–0.63),
without heterogeneity (I2 = 0%, p = 0.562). For women
who have ever smoked, the summary RR was 0.90 (95%
CI, 0.67–1.21) for ever versus nulliparous, without
heterogeneity (I2 = 0%, p = 0.531).
Differences with parity number
Six cohort and six case-control studies investigated
possible association between parity and BC risk. The
results of the effects of different parity number on BC
risk are presented in Table 2. To clarify the effects, we
divided the parity number into three groups. The first
group (1–2 births) contained seven reports, compared
with nulliparous,, the pooled RR of BC associated with
giving birth to two children was 0.82 (95% CI 0.71–0.94)
with I2 = 17.7% (P = 0.295). The second group (3–4
births) contained seven reports, compared with nullipa-
rous, the overall RR of BC was 0.79 (95% CI 0.68–0.91)
with I2 = 0% (P = 0.997). The third group (≥5 births)
contained six reports, compared with nulliparous, the
overall RR of BC was 0.76 (95% CI 0.66–0.88) with I2 = 0%
(P = 0.994).
Dose-response meta-analysis
Dose-response from nine studies [6, 8, 11–13, 20–23]
showed a decreased in BC risk of 0.95 (95% CI: 0.92–0.98)
per live birth increase, without heterogeneity (I2 = 12.79%,
P = 0.7832). Compared with nulliparous individuals, the
pooled RRs (95% CI) of BC were 0.84 (0.76–0.94), 0.76
(0.67–0.87), 0.74 (0.65–0.85), 0.75 (0.66–0.85), and 0.76
(0.65–0.88) for 1, 2, 3, 4, and 5 live births, respectively
(Fig. 3).
Publication bias
No evidence of a significant publication bias was
observed in our analyses as assessed using the Egger’s
Fig. 2 Forest plot (fixed-effects model) of ever parity and bladder cancer risk
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test or Begg’s test and no asymmetry was seen in the
funnel plots of included studies.
Subgroup analyses
To avoid the influence of cigarette smoking, we evaluated
the influence of smoking status by adjustment in the eight
reports that considered smoking. However, when data
were stratified by adjustment for smoking, we did not find
a significant difference between summary RRs that were
adjusted and those that were not adjusted for smoking
(Table 2). Moreover, significant inverse associations were
persisted after the subgroup analyses stratified by whether
the study included adjustment for specific potential
confounders, such as age, Body Mass Index (BMI), type of
control subjects or others potential confounders (Table 2).
An additional file shows this in more detail (see
Additional file 1).
Discussion
Numerous epidemiological studies have focused on BC
risk factors in order to explain the gender disparity in
BC incidence, while there is also a great interest in iden-
tifying factors that affect the risk of BC among women.
Although previous studies have reported on the associa-
tions between parity and BC, to the best of our know-
ledge, no other earlier studies have clearly documented a
dose-response pattern between parity number and BC
risk. In present study, we conducted a dose-response
meta-analysis to characterize the association between
parity and BC risk. Findings from the present study indi-
cated that parous was significantly inversely associated
with BC risk compared with nulliparous, especially for
non-smokers. Overall, the risk of BC decreased by 24%
for women who had given birth and 53% for those who
had never smoked and were ever parous.
Although the exact mechanisms underlying this inverse
association between parity and BC risk are not completely
established, several potential mechanisms have been
proposed. First, during pregnancy, estrogen and progester-
one levels increase drastically and induce substantial
alterations to the structure, function, and histology of the
bladder [25], possibly affecting the development and pro-
gression of BC. Both estrogen and progesterone receptors
are found in bladder tissues suggesting that endocrine
regulation could directly influence BC development [26].
Shen et al. [27] found that antiestrogens have an inhibitory
effect on the growth of BC cells in vitro, indicating that
estrogens may increase the development and growth of
bladder malignancies. Some research has reported that
progesterone suppresses the activity of the estrogen
receptor during pregnancy [28]. Therefore, estrogen and
progesterone have an antagonistic effects on human cells.
The substantial increased in their levels during pregnancy
may responsible for the decreased risk of BC for women.
Table 2 Summary risk estimates of the association between
parity and bladder cancer
No. of reports RR (95% CI) I2 (%) P value
Overall 13 0.76 (0.70–0.82) 0 0.795
Number of parity
1 ~ 2 vs. 0 7 0.82 (0.71–0.94) 17.7 0.295
3 ~ 4 vs. 0 7 0.79 (0.68–0.91) 0 0.997
≥ 5 vs. 0 6 0.76 (0.66–0.88) 0 0.994
Subgroup analysis
Study design
Cohort study 6 0.77 (0.71–0.84) 0 0.802
Case-control study 7 0.71 (0.60–0.83) 0 0.598
Number of cases
< 250 7 0.68 (0.56–0.81) 0 0.673
> 250 6 0.78 (0.71–0.84) 0 0.841
Location
USA 9 0.72 (0.65–0.81) 0 0.989
Others 4 0.79 (0.71–0.87) 39.7 0.174
Smoking
Never smoking 5 0.47 (0.35–0.63) 0 0.562
Ever smoking 4 0.90 (0.67–1.21) 0 0.531
Adjustment for smoking
Yes 8 0.67 (0.57–0.79) 0 0.815
No 5 0.79 (0.72–0.86) 0 0.882
Adjustment for age
Yes 9 0.77 (0.71–0.84) 0 0.850
No 4 0.65 (0.52–0.81) 0 0.684
Adjustment for BMI
Yes 5 0.66 (0.53–0.81) 0 0.469
No 8 0.76 (0.70–0.82) 0 0.952
Fig. 3 Nonlinear dose-response relationship between parity and
bladder cancer risk
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Moreover, a hormone-related protective effect based on the
prity number may mirror the lifetime period of lactation
and prolonged oxytocin inhibition of steroid hormones [6].
Second, smoking habits may have influenced the
incidence of BC in women with parity. It is well known
that prenatal cigarette smoking exposure may cause
detrimental effects on reproductive health [29]. There-
fore, most smokers who prepare for pregnancy are more
likely to quit smoking. Thus, compared with nulliparous
female smokers, parous smokers who quit smoking may
have a shorter smoking exposure history and reduction
of pack years, and this may affect their BC risk. In
addition, cumulative effect of abandon smoking follow-
ing multiple pregnancies may also associate to decrease
the subsequent risk of BC. The findings of our study
suggest that the negative correlation between parity and
BC appears more remarkable among women who were
never exposed to cigarettes, with these parous women ex-
periencing at least a 53% decreased risk of BC compared
with nulliparous women. However, such a dramatic risk
reduction was not apparent among smokers. The reasons
for this results of subgroup analysis may be that the effect
of smoking on BC is so huge that for the development of
the disease minor influence factors such as parity are less
relevant. In case of never smokers, these minor influence
factors play indeed a role.
Third, structural changes in the pelvic organs and pelvic
floor organization following pregnancy may induce a
decreased risk for BC in parous women. Childbirth is an
established risk factor for lower urinary tract dysfunction,
such as increased urinary frequency, stress incontinence,
and overactive bladder [30], but the possible relationship
with BC remains unclear. It is well known that BC risk is
related to the contact time of the urothelium with carcino-
gens in urine. Some study reported that increased water
intake and urination frequency may lessen contact time of
urinary carcinogens with urothelium of the bladder, thus,
diminish the bladder cancer risk [31, 32]. Zhang et al. [31]
found that increasing urination frequency during daytime
was associated with decreased risk of bladder cancer.
Silverman et al. [32] suggested that nocturia may be a
powerful factor in reducing BC risk. Based on the
results of above studies, we can be reasonable to
assume that lower urinary tract dysfunction after
childbirth has a protective effect on BC risk, and this
may be associated with shorter duration of exposure
to urine carcinogens in the bladder. Further research
should verify this hypothesis.
Meta-analyses of observational studies are prone to
confounding, selection, and information bias as the
included observational studies and can present par-
ticular challenges that may distort the results. How-
ever, our study has some strengths. First, we searched
2 electronic databases, which ensured a broad scope,
and we included seven cohorts and seven case-control
studies that involved a total of 6,214 cases and
2,693,350 non-cases. This large sample size should
have provided sufficient statistical power to detect this
potential relationship. Second, to control misclassification,
we conducted a dose-response meta-analysis. This is the
most comprehensive meta-analysis evaluating the associa-
tions between parity and BC. Third, no publication biases
were detected in present study and outcome may be
unlikely to remain unreported as studies with complex
assessment of exposure.
Conclusions
This current dose-response meta-analysis indicates that
women with parity have an inversely associated BC risk
compared with nulliparous women. The exact mechan-
ism underlying this protective effect requires further
investigation.
Additional file
Additional file 1: Subgroup analyses of forest plots included in our
meta-analysis. (ZIP 143 kb)
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